FOLLICULAR LYMPHOMAS ARE CURABLE DISEASES. DATA FROM A RETROSPECTIVE STUDY ON 133 PATIENTS WITH AT LEAST 10 YEARS OF OBSERVATION.
(Abstract release date: 05/19/16)
EHA Library. Kovalchuk S. 06/09/16; 132715; E1166
Dr. Sofia Kovalchuk
Contributions
Contributions
Abstract
Abstract: E1166
Type: Eposter Presentation
Background
Follicular lymphomas are usually defined as incurable diseases with a natural history characterized by continuous relapses. This study was launched to evaluate how many patients, after a long observation period, do not relapse or do not experience a new treatment.
Aims
The aim of the study was to identify which clinical characteristics or therapeutical approaches are associated with this cohort of favourable patients.
Methods
All patients with histologically confirmed diagnosis of follicular lymphomas grade I-II or IIIa were selected from our data base starting from January 2000 untill December 2004 in such a way to have at least 10 years of observation for alive patients. We considered patients obtaining at least a partial response and we divided patients in two cohorts, cohort 1 with patients relapsed or progressed and cohort 2 with patients never relapsed or progressed.
Results
One hundred and fourthy-six patients were diagnosed and treated at our Institution. Thirteen patients were excluded from the analysis, 8 lost to the follow-up and 5 did not obtained at least a partial remission. Finally 133 patients were analysed for the study. The median age at diagnosis was 61 years (range 30-87). Stage I-II in 47 patients, III-IV in 86. Bone marrow biopsy was positive in 87 patients, FLIPI 0-1 in 35, FLIPI 2 in 43, FLIPI 3 in 40 and FLIPI 4 in 15 patients. According to treatment 96 patients were treated with antracycline containing regimens, 24 with fludarabine containing regimens and 13 were observed or treated with radiotherapy. Rituximab was used in 92 patients, as sequential treatment in 70 or chemotherapy combined in 22; 41 patients did not use rituximab.We analysed cohort 1 (85 patients) and cohort 2 (48 patients) and the statistically significant differences between the two cohorts were: elderly patients (p 0.05), symptomatic patients (p 0.05), FLIPI and FLIPI2 high score (p 0.005), lack of complete remission (p 0.0000) all observed in cohort 1. The overall survival with a median period of observation of 127 months (range 2-196) was 71%, considering the two groups the overall survival in cohort 1 was 62% with a median of 142 months and it was 94% in cohort 2 with median not reached. In univariate analysis normal value of beta2 microglobulin (p 0.05) and the use of rituximab (p 0.01) were associated with a better overall survival; in multivariate analysis treatment with rituximab manteined a statistically significance.
Conclusion
In conclusion this retrospective monocentric study confirms that about one third of follicular lymphoma patients could be considered cured particularly if rituximab was used in the treatment. At the present time all patients with follicular lymphoma are treated with combined immuno-chemotherapy, moreover after induction therapy patients are started with manteinance. We can therefore hope for the future in an improvement of survival results.
Session topic: E-poster
Keyword(s): Follicular lymphoma, Long-term follow-up
Type: Eposter Presentation
Background
Follicular lymphomas are usually defined as incurable diseases with a natural history characterized by continuous relapses. This study was launched to evaluate how many patients, after a long observation period, do not relapse or do not experience a new treatment.
Aims
The aim of the study was to identify which clinical characteristics or therapeutical approaches are associated with this cohort of favourable patients.
Methods
All patients with histologically confirmed diagnosis of follicular lymphomas grade I-II or IIIa were selected from our data base starting from January 2000 untill December 2004 in such a way to have at least 10 years of observation for alive patients. We considered patients obtaining at least a partial response and we divided patients in two cohorts, cohort 1 with patients relapsed or progressed and cohort 2 with patients never relapsed or progressed.
Results
One hundred and fourthy-six patients were diagnosed and treated at our Institution. Thirteen patients were excluded from the analysis, 8 lost to the follow-up and 5 did not obtained at least a partial remission. Finally 133 patients were analysed for the study. The median age at diagnosis was 61 years (range 30-87). Stage I-II in 47 patients, III-IV in 86. Bone marrow biopsy was positive in 87 patients, FLIPI 0-1 in 35, FLIPI 2 in 43, FLIPI 3 in 40 and FLIPI 4 in 15 patients. According to treatment 96 patients were treated with antracycline containing regimens, 24 with fludarabine containing regimens and 13 were observed or treated with radiotherapy. Rituximab was used in 92 patients, as sequential treatment in 70 or chemotherapy combined in 22; 41 patients did not use rituximab.We analysed cohort 1 (85 patients) and cohort 2 (48 patients) and the statistically significant differences between the two cohorts were: elderly patients (p 0.05), symptomatic patients (p 0.05), FLIPI and FLIPI2 high score (p 0.005), lack of complete remission (p 0.0000) all observed in cohort 1. The overall survival with a median period of observation of 127 months (range 2-196) was 71%, considering the two groups the overall survival in cohort 1 was 62% with a median of 142 months and it was 94% in cohort 2 with median not reached. In univariate analysis normal value of beta2 microglobulin (p 0.05) and the use of rituximab (p 0.01) were associated with a better overall survival; in multivariate analysis treatment with rituximab manteined a statistically significance.
Conclusion
In conclusion this retrospective monocentric study confirms that about one third of follicular lymphoma patients could be considered cured particularly if rituximab was used in the treatment. At the present time all patients with follicular lymphoma are treated with combined immuno-chemotherapy, moreover after induction therapy patients are started with manteinance. We can therefore hope for the future in an improvement of survival results.
Session topic: E-poster
Keyword(s): Follicular lymphoma, Long-term follow-up
Abstract: E1166
Type: Eposter Presentation
Background
Follicular lymphomas are usually defined as incurable diseases with a natural history characterized by continuous relapses. This study was launched to evaluate how many patients, after a long observation period, do not relapse or do not experience a new treatment.
Aims
The aim of the study was to identify which clinical characteristics or therapeutical approaches are associated with this cohort of favourable patients.
Methods
All patients with histologically confirmed diagnosis of follicular lymphomas grade I-II or IIIa were selected from our data base starting from January 2000 untill December 2004 in such a way to have at least 10 years of observation for alive patients. We considered patients obtaining at least a partial response and we divided patients in two cohorts, cohort 1 with patients relapsed or progressed and cohort 2 with patients never relapsed or progressed.
Results
One hundred and fourthy-six patients were diagnosed and treated at our Institution. Thirteen patients were excluded from the analysis, 8 lost to the follow-up and 5 did not obtained at least a partial remission. Finally 133 patients were analysed for the study. The median age at diagnosis was 61 years (range 30-87). Stage I-II in 47 patients, III-IV in 86. Bone marrow biopsy was positive in 87 patients, FLIPI 0-1 in 35, FLIPI 2 in 43, FLIPI 3 in 40 and FLIPI 4 in 15 patients. According to treatment 96 patients were treated with antracycline containing regimens, 24 with fludarabine containing regimens and 13 were observed or treated with radiotherapy. Rituximab was used in 92 patients, as sequential treatment in 70 or chemotherapy combined in 22; 41 patients did not use rituximab.We analysed cohort 1 (85 patients) and cohort 2 (48 patients) and the statistically significant differences between the two cohorts were: elderly patients (p 0.05), symptomatic patients (p 0.05), FLIPI and FLIPI2 high score (p 0.005), lack of complete remission (p 0.0000) all observed in cohort 1. The overall survival with a median period of observation of 127 months (range 2-196) was 71%, considering the two groups the overall survival in cohort 1 was 62% with a median of 142 months and it was 94% in cohort 2 with median not reached. In univariate analysis normal value of beta2 microglobulin (p 0.05) and the use of rituximab (p 0.01) were associated with a better overall survival; in multivariate analysis treatment with rituximab manteined a statistically significance.
Conclusion
In conclusion this retrospective monocentric study confirms that about one third of follicular lymphoma patients could be considered cured particularly if rituximab was used in the treatment. At the present time all patients with follicular lymphoma are treated with combined immuno-chemotherapy, moreover after induction therapy patients are started with manteinance. We can therefore hope for the future in an improvement of survival results.
Session topic: E-poster
Keyword(s): Follicular lymphoma, Long-term follow-up
Type: Eposter Presentation
Background
Follicular lymphomas are usually defined as incurable diseases with a natural history characterized by continuous relapses. This study was launched to evaluate how many patients, after a long observation period, do not relapse or do not experience a new treatment.
Aims
The aim of the study was to identify which clinical characteristics or therapeutical approaches are associated with this cohort of favourable patients.
Methods
All patients with histologically confirmed diagnosis of follicular lymphomas grade I-II or IIIa were selected from our data base starting from January 2000 untill December 2004 in such a way to have at least 10 years of observation for alive patients. We considered patients obtaining at least a partial response and we divided patients in two cohorts, cohort 1 with patients relapsed or progressed and cohort 2 with patients never relapsed or progressed.
Results
One hundred and fourthy-six patients were diagnosed and treated at our Institution. Thirteen patients were excluded from the analysis, 8 lost to the follow-up and 5 did not obtained at least a partial remission. Finally 133 patients were analysed for the study. The median age at diagnosis was 61 years (range 30-87). Stage I-II in 47 patients, III-IV in 86. Bone marrow biopsy was positive in 87 patients, FLIPI 0-1 in 35, FLIPI 2 in 43, FLIPI 3 in 40 and FLIPI 4 in 15 patients. According to treatment 96 patients were treated with antracycline containing regimens, 24 with fludarabine containing regimens and 13 were observed or treated with radiotherapy. Rituximab was used in 92 patients, as sequential treatment in 70 or chemotherapy combined in 22; 41 patients did not use rituximab.We analysed cohort 1 (85 patients) and cohort 2 (48 patients) and the statistically significant differences between the two cohorts were: elderly patients (p 0.05), symptomatic patients (p 0.05), FLIPI and FLIPI2 high score (p 0.005), lack of complete remission (p 0.0000) all observed in cohort 1. The overall survival with a median period of observation of 127 months (range 2-196) was 71%, considering the two groups the overall survival in cohort 1 was 62% with a median of 142 months and it was 94% in cohort 2 with median not reached. In univariate analysis normal value of beta2 microglobulin (p 0.05) and the use of rituximab (p 0.01) were associated with a better overall survival; in multivariate analysis treatment with rituximab manteined a statistically significance.
Conclusion
In conclusion this retrospective monocentric study confirms that about one third of follicular lymphoma patients could be considered cured particularly if rituximab was used in the treatment. At the present time all patients with follicular lymphoma are treated with combined immuno-chemotherapy, moreover after induction therapy patients are started with manteinance. We can therefore hope for the future in an improvement of survival results.
Session topic: E-poster
Keyword(s): Follicular lymphoma, Long-term follow-up
{{ help_message }}
{{filter}}